Incidence of SAD (SIGH‐SAD score ≥ 20) ( · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL probably leads to lower incidence of SAD (SIGH‐SAD score ≥ 20) compared with placebo (moderate certainty).
1 finding from 1 review
Overall rate of adverse events · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL showed no clear difference in overall rate of adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Headache · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL probably leads to higher headache compared with placebo (moderate certainty).
1 finding from 1 review
Insomnia · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL may leads to higher insomnia compared with placebo (low certainty).
1 finding from 1 review
Nausea · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL may leads to higher nausea compared with placebo (low certainty).
1 finding from 1 review
Diarrhoea · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL showed no clear difference in diarrhoea compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL showed no clear difference in discontinuation due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Endpoint scale total scores (150 mg twice daily dose) (Scales of sexual functioning. As studies used different scales to assess sexual functioning, differences are expressed as standardised mean differences (SMD)) · people with antidepressant‐induced sexual dysfunction
1 finding from 1 review
Effect on later sexual function · people with antidepressant‐induced sexual dysfunction
Bupropion showed no clear difference in 50% reduction in score on the Arizona Sexual Experiences Scale… compared with placebo (moderate certainty).
1 finding from 1 review
Dropout · people with antidepressant‐induced sexual dysfunction
Bupropion showed no clear difference in dropouts (People leaving the trial early) compared with placebo (high certainty).
1 finding from 1 review
Failure to respond at endpoint (6‐12 weeks) · patients with depression
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with bupropion (moderate certainty).
1 finding from 1 review
Failure to respond at 1‐4 weeks · patients with depression
1 finding from 1 review
Failure to respond at 16‐24 weeks · patients with depression
1 finding from 1 review
Failure to remit at endpoint · patients with depression
1 finding from 1 review
SMD at endpoint · patients with depression
1 finding from 1 review
Failure to complete ‐ any cause ‐ · patients with depression
Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ compared with bupropion (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · patients with depression
Paroxetine showed no clear difference in participants with at least some Side Effects compared with bupropion (moderate certainty).
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with bupropion (moderate certainty).
1 finding from 1 review
Endpoint score (HDRS or MADRS) · patients with depression
1 finding from 1 review
Failure to complete ‐ total ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with bupropion (moderate certainty).
1 finding from 1 review